Skip to main content

Table 4 Response of 16 individuals with CDD to vagus nerve stimulator

From: Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder

Subject ID

Age at placement

Seizure frequency at start of VNS

Seizure response

Side effects

A11

Unknown

Daily

No change in seizures

None reported

A20

9 years 4 months

2–3/day

Decreased frequency and severity, decreased duration with magnet

Initial increase in frequency of seizures prior to adjustment of settings

A21

6 years 3 months

5–6/day

Decreased severity

None reported

A24

1 year 9 months

Daily

Decreased frequency and severity

Swallowing difficulties

A25

4 years 3 months

Daily

Minimal effect

None reported

A26

4 years

Unknown

Decreased frequency

None reported

A28

3 years 2 months

Daily

Decreased frequency

Initial increase in severity of seizures

A31

2 years 8 months

8–10 clusters/day

Decreased frequency, response to magnet

None reported

A35

10 years

Weekly

Decreased duration

None reported

A79

13 years

Unknown

Decreased duration

None reported

B7

7.5 years

Daily

No change in seizures

None reported

B8

5 years

Daily

No change in seizures

None reported

B11

Unknown

Daily

No change in seizures

None reported

B14

Unknown

Daily

Unknown

Unknown

B15

2 years 3 months

Daily

Slight reduction in seizures

None reported

B22

7 years

10–14/day

Reduced seizures to 5–6/day

None reported